Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 36Pemetrexed 28Bevacizumab 26Cisplatin 24Paclitaxel 22Gemcitabine 20Radiotherapy 18Docetaxel 18Erlotinib Hydrochloride 15Gefitinib 11pembrolizumab 6Cetuximab 6capmatinib 5Surgical Procedures, Operative 5Radiosurgery 5aflutinib 4Vinorelbine 4Taxes 4Platinum 4Nivolumab 4Metformin 4pegfilgrastim 3durvalumab 3ceritinib 3apatinib 3Sorafenib 3Radiation 3Neoadjuvant Therapy 3Magnetic Resonance Spectroscopy 3tislelizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma of Lung × methoxyamine × Clear all
NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
42 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡